The dominant-negative effect of p53 mutants and p21 induction in tetraploid G1 arrest depends on the type of p53 mutation and the nature of the stimulus

Cancer Genetics and Cytogenetics

Volumn 143, Issue 1, 2003, Pages 39-49

  Dridi, Walid ^a   Fetni, Raouf ^b   Lavoie, Josée ^a   Poupon, Marie France ^c   Drouin, Régen ^a  

^a LAVAL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

^c INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; BROXURIDINE; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL LINE; COLON CARCINOMA; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; IMMUNOCYTOCHEMISTRY; IONIZING RADIATION; MITOSIS INHIBITION; MITOSIS SPINDLE; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPHOSPHORYLATION; PROTEIN INDUCTION; STIMULUS; STIMULUS RESPONSE; TETRAPLOIDY; WILD TYPE;

EID: 0037992507     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00837-3     Document Type: Article

References (61)

1. Galipeau P.C., Prevo L.J., Sanchez C.A., Longton G.M., Reid B.J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst. 91:1999;2087-2095.
2. Shackney S.E., Smith C.A., Miller B.W., Burholt D.R., Murtha K., Giles H.R., Ketterer D.M., Pollice A.A. Model for the genetic evolution of human solid tumors. Cancer Res. 49:1989;3344-3354.
3. Neshat K., Sanchez C.A., Galipeau P.C., Blount P.L., Levine D.S., Joslyn G., Reid B.J. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology. 106:1994;1589-1595.
4. Muleris M., Salmon R.J., Dutrillaux B. Existence of two distinct processes of chromosomal evolution in near- diploid colorectal tumors. Cancer Genet Cytogenet. 32:1988;43-50.
5. Vogelstein B., Kinzler K.W. Carcinogens leave fingerprints. Nature. 355:1992;209-210.
6. Hann B.C., Lane D.P. The dominating effect of mutant p53. Nat Genet. 9:1995;221-222.
7. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
8. Brachmann R.K., Vidal M., Boeke J.D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA. 93:1996;4091-4095.
9. Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
10. Srivastava S., Wang S., Tong Y.A., Pirollo K., Chang E.H. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene. 8:1993;2449-2456.
11. Unger T., Mietz J.A., Scheffner M., Yee C.L., Howley P.M. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol. 13:1993;5186-5194.
12. Chene P. In vitro analysis of the dominant negative effect of p53 mutants. J Mol Biol. 281:1998;205-209.
13. Pocard M., Chevillard S., Villaudy J., Poupon M.F., Dutrillaux B., Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene. 12:1996;875-882.
14. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Felix A., Neri A. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene. 13:1996;2477-2482.
15. Chen J.Y., Funk W.D., Wright W.E., Shay J.W., Minna J.D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene. 8:1993;2159-2166.
16. Rolley N., Butcher S., Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene. 11:1995;763-770.
17. Williams A.C., Miller J.C., Collard T.J., Bracey T.S., Cosulich S., Paraskeva C. Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene. 11:1995;141-149.
18. Hinds P.W., Finlay C.A., Quartin R.S., Baker S.J., Fearon E.R., Vogelstein B., Levine A.J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells. a comparison of the "hot spot" mutant phenotypes Cell Growth Differ. 1:1990;571-580.
19. Dulic V., Kaufmann W.K., Wilson S.J., Tlsty T.D., Lees E., Harper J.W., Elledge S.J., Reed S.I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
20. Liu P.K., Kraus E., Wu T.A., Strong L.C., Tainsky M.A. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene. 12:1996;2267-2278.
21. Zeng Y.X., el-Deiry W.S. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene. 2:1996;1557-1564.
22. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., Vogelstein B., Jacks T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:1995;935-944.
23. Loignon M., Fetni R., Gordon A.J., Drobetsky E.A. A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res. 57:1997;3390-3394.
24. Andreassen P.R., Lohez O.D., Lacroix F.B., Margolis R.L. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell. 12:2001;1315-1328.
25. Andreassen P.R., Margolis R.L. Microtubule dependency of p34cdc2 inactivation and mitotic exit in mammalian cells. J Cell Biol. 127:1994;789-802.
26. Kung A.L., Sherwood S.W., Schimke R.T. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA. 87:1990;9553-9557.
27. Rieder C.L., Palazzo R.E. Colcemid and the mitotic cycle. J Cell Sci. 102:1992;387-392.
28. Lanni J.S., Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 18:1998;1055-1064.
29. Drouin R., Lemieux N., Richer C.L. High-resolution R-banding at the 1250-band level. 1. Technical considerations on cell synchronization and R-banding (RHG and RbG). Cytobios. 56:1988;107-125.
30. Koch J., Hindkjaer J., Kolvraa S., Bolund L. Construction of a panel of chromosome-specific oligonucleotide probes (PRINS-primers) useful for the identification of individual human chromosomes in situ. Cytogenet Cell Genet. 71:1995;142-147.
31. Lalande M.A. Reversible arrest point in the late G1 phase of the mammalian cell cycle. Exp Cell Res. 186:1990;332-339.
32. Masramon L., Ribas M., Cifuentes P., Arribas R., Garcia F., Egozcue J., Peinado M.A., Miro R. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet Cytogenet. 121:2000;17-21.
33. Buchkovich K., Duffy L.A., Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell. 58:1989;1097-1105.
34. Tamrakar S., Rubin E., Ludlow J.W. Role of pRb dephosphorylation in cell cycle regulation. Front Biosci. 5:2000;D121-D137.
35. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. Science. 271:1996;1744-1747.
36. Brown K., Kemp C., Burns P., Balmain A. Importance of genetic alterations in tumour development. Arch Toxicol Suppl. 16:1994;253-260.
37. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., Raskind W.H., Reid B.J. A p53-dependent mouse spindle checkpoint. Science. 267:1995;1353-1356.
38. Di Leonardo A., Khan S.H., Linke S.P., Greco V., Seidita G., Wahl G.M. DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57:1997;1013-1019.
39. Minn A.J., Boise L.H., Thompson C.B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 10:1996;2621-2631.
40. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:1995;5187-5190.
41. Mantel C., Braun S.E., Reid S., Henegariu O., Liu L., Hangoc G., Broxmeyer H.E. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood. 93:1999;1390-1398.
42. Matsuura S., Ito E., Tauchi H., Komatsu K., Ikeuchi T., Kajii T. Chromosomal instability syndrome of total premature chromatid separation with mosaic variegated aneuploidy is defective in mitotic-spindle checkpoint. Am J Hum Genet. 67:2000;483-486.
43. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
44. Grana X., Reddy E.P. Cell cycle control in mammalian cells. role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene. 11:1995;211-219.
45. Morgan D.O. Principles of CDK regulation. Nature. 374:1995;131-134.
46. Khan S.H., Wahl G.M. p53 and pRb prevent rereplication in response to microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res. 58:1998;396-401.
47. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
48. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
49. Gu X.F., Allain A., Li L., Cramer E.M., Tenza D., Caen J.P., Han Z.C. Expression of cyclin B in megakaryocytes and cells of other hematopoietic lines. C R Acad Sci III. 316:1993;1438-1445.
50. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
51. Sherr C.J. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians. 107:1995;181-186.
52. Gujuluva C.N., Baek J.H., Shin K.H., Cherrick H.M., Park N.H. Effect of UV-irradiation on cell cycle, viability and the expression of p53, gadd153 and gadd45 genes in normal and HPV-immortalized human oral keratinocytes. Oncogene. 9:1994;1819-1827.
53. Haapajarvi T., Kivinen L., Pitkanen K., Laiho M. Cell cycle dependent effects of u.v.-radiation on p53 expression and retinoblastoma protein phosphorylation. Oncogene. 11:1995;151-159.
54. Orren D.K., Petersen L.N., Bohr V.A. A UV-responsive G2 checkpoint in rodent cells. Mol Cell Biol. 15:1995;3722-3730.
55. Liu V.F., Boubnov N.V., Weaver D.T. Cell cycle checkpoints and repair of ionizing radiation damage. Stem Cells. 13(Suppl. 1):1995;117-128.
56. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1998;1497-1501.
57. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:1995;675-684.
58. Ruiz-Lozano P., Hixon M.L., Wagner M.W., Flores A.I., Ikawa S., Baldwin A.S., Chien K.R., Gualberto A. p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth Differ. 10:1999;295-306.
59. Hixon M.L., Flores A., Wagner M., Gualberto A. Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint. Histol Histopathol. 15:2000;551-556.
60. Gualberto A., Aldape K., Kozakiewicz K., Tlsty T.D. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci USA. 95:1998;5166-5171.
61. Notterman D., Young S., Wainger B., Levine A.J. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity. Oncogene. 17:1998;2743-2751.